Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. reports the results of the Annual General Meeting (AGM) held on June 3, 2025, in Amsterdam, the Netherlands. The meeting addressed governance matters, financial approvals for the 2024 fiscal year, and authorizations for share issuance and repurchase.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholder voting outcomes regarding the adoption of the 2024 annual accounts rather than detailing the financial figures themselves.
Material Changes and Voting Results
Shareholders approved all agenda items submitted for a vote. Key outcomes include:
- Adoption of 2024 Annual Accounts: Approved with 99.9% of votes cast in favor.
- Release from Liability: Board members were released from liability for the 2024 financial year with 99.5% approval.
- Board Re-appointments: James Shannon (non-executive) was re-appointed with 80.7% support; Daniel de Boer (executive) was re-appointed with 86.3% support.
- Auditor Appointment: KPMG Accountants N.V. was appointed as the external auditor for the 2026 financial year with 99.8% approval.
- Share Capital Authorization: The Board was authorized to issue ordinary shares (78.5% approval) and acquire ordinary shares (83.2% approval).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of the AGM results.
Investor Verification Checklist
- Verify the specific financial figures for the 2024 fiscal year in the Company's Form 20-F or annual report, as they are not detailed in this filing.
- Confirm the scope and duration of the Board's new authorization to issue and repurchase shares.
- Review the full text of the 2024 annual accounts to understand the "net result" appropriation approved by shareholders.